YOU GENE

Brand Owner (click to sort) Address Description
YOUGENE Genelex Corporation 3101 Western Ave., Ste 100 Seattle WA 98121 YOU GENE;Providing on-line non-downloadable software for consumers featuring drug-drug and drug-gene interaction information and adverse drug reaction information;
YOUGENE YouGene 175 Varick St New York NY 10069 YOU GENE;Providing genomic and molecular medical information and services to patients, medical professionals, patent owners, clinicians, and insurers in the fields of diagnosis of disease and pharmaceutical-genomic and -proteomic interactions; Providing genomic bio-banking services for organizations, patients, consumers, and clinicians and facilitating privacy of genomic data; Delivering genomic screening and analysis services for scientific, research, and clinical purposes; Providing administration and payments services for insurance, royalty, and financial transactions related to medical genetic testing, Determining the presence of biomarkers in genetic samples; Facilitating intellectual property rights transfers to search for proprietary biomarkers and storage of genetic information; Providing services to providers of electronic medical and health record;
YOUGENE YouGene, Corp 175 Varick St New York NY 10014 YOU GENE;Providing medical and scientific research information in the nature of genomic, genetic database, variant classification, algorithms and molecular medical information to patients, medical professionals, patent owners, clinicians and insurers in the fields of diagnosis of disease and pharmaceutical genomic and proteomic interactions; Providing genomic bio-banking services in the nature of gene bank services for organizations, patients, consumers, and clinicians for research purposes; delivering genomic screening and analysis services for scientific, research, and clinical research purposes, namely, determining the presence of biomarkers in genetic samples;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention comprises a method for producing mammalian therapeutics free from prion contamination and cells for use in such methods. Such therapeutics are produced in somatic cells having a genome with an artificially altered PrP gene. The PrP gene in these cells may be ablated, or replaced by an exogenous inducible form of the PrP gene. The endogenous gene in the host cells may be disrupted, or disrupted and replaced by an exogenous PrP gene.